Plerixafor for autologous CD34+ cell mobilization

Huda Salman, Hillard M. Lazarus

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34 + cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalCore Evidence
StatePublished - Feb 7 2011
Externally publishedYes


  • Autologous hematopoietic cell transplant
  • CD34
  • Granulocyte colony-stimulating factor (G-CSF)
  • Lymphoma
  • Myeloma
  • Plerixafor

ASJC Scopus subject areas

  • Reviews and References, Medical
  • Pharmacology


Dive into the research topics of 'Plerixafor for autologous CD34+ cell mobilization'. Together they form a unique fingerprint.

Cite this